Application of anacridine in treatment of beta-catenin mutant liver cancer

• Main Authors: SUN JINGYUAN, HE XINRONG, XIAO YAZHI, CAO CHUANHUI, GAO XINNA, CHEN YIYAO, LUO YONGYI
• Format: Patent
• Language: Chinese; English
• Published: 17.10.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention provides application of anacridine in treatment of beta-catenin mutant liver cancer, and belongs to the technical field of medicines. Drug screening finds that the anacridine specifically kills the beta-catenin mutant liver cancer, and animal experiments prove that the low-dose anacridine has a treatment effect on the beta-catenin mutant liver cancer, the side effect of the drug is small, and the treatment effect on the beta-catenin wild type liver cancer is poor. Therefore, the clinical application range of amacridine treatment is widened, and the technical problem that amacridine is not well applied to solid tumors is solved. 本发明提供安吖啶在治疗β-catenin突变型肝癌中的应用，属于医药技术领域。本发明通过药物筛选发现安吖啶特异性杀伤β-catenin突变型肝癌，并在动物实验上证明了低剂量安吖啶对β-catenin突变肝癌具有治疗效应，药物副作用小，对β-catenin野生型肝癌治疗不佳。可见本发明拓宽了安吖啶治疗的临床适用范围，解决了安吖啶在实体肿瘤应用不佳的技术问题。